Diagnosis made clear through Presepsin testing

30 Jun 2026

This brochure explores the clinical utility of Presepsin (sCD14-ST), a biomarker that rises early during bacterial infection and sepsis. Discover how Presepsin testing can support early diagnosis, ongoing treatment monitoring, and risk stratification, providing clinicians with valuable information alongside other diagnostic tools as part of a comprehensive sepsis management strategy.

The assay is available on AIA®-360 and AIA®-CL300 analyzers from Tosoh Bioscience - Diagnostics EMEA, delivering results in approximately 15–20 minutes for rapid clinical decision-making in emergency and critical care settings. The brochure also outlines the biological role of Presepsin in the innate immune response and its growing evidence base in sepsis diagnosis and prognosis.

Resource details

  • Resource type: Product brochure
  • Page count: 8
  • Read time: 12 mins

Links

Tags

BiomarkersBiomarkers are biological markers which can be measured and evaluated to indicate a biological state. The use of biomarkers in research and diagnosis can indicate a normal or disease state or drug response of cells / tissues. Biomarkers include genetic markers, cell surface markers such as antigens, antibodies or receptors and secreted molecules such as cytokines. An assay system is required for identification of biomarkers. :SepsisSepsis is a life-threatening response to infection causing organ dysfunction. Research focuses on early detection, biomarkers, and therapies to reduce mortality. Explore tools for sepsis diagnostics and analysis in our peer-reviewed product directory, including detection kits and biomarkers.Infectious DiseaseInfectious disease diagnostics refers to the isolation and identification of causative agents, such as viruses, bacteria or fungi. Diagnostic tests include bacterial culture, microscopy, chemistry assays, molecular diagnostics and MALDI-TOF. Tests can be carried out in the laboratory or at the point-of-care.